SCHEMBL3634273

SCHEMBL3634273

OCc1ccc(N(Cc2ccccc2)Cc2ccccc2)cc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C19 P33261 1/20 0.62
TSHR P16473 4/20 0.58
NR1H2 P55055 3/20 0.54
NR1H3 Q13133 3/20 0.54
CNR2 P34972 4/20 0.53
NR3C1 P04150 1/20 0.53
LTA4H P09960 1/20 0.45
CYP2D6 P10635 2/20 0.45
TAAR1 Q96RJ0 2/20 0.45
LMNA P02545 2/20 0.45
CYP1A2 P05177 1/20 0.45
HTR1A P08908 1/20 0.45
ADRA2A P08913 1/20 0.45
ADORA3 P0DMS8 1/20 0.45
PDE6A P16499 1/20 0.45
ADRA2C P18825 1/20 0.45
MC4R P32245 1/20 0.45
ADRA1A P35348 1/20 0.45
HRH1 P35367 1/20 0.45
OPRM1 P35372 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2960872 0.87 CYP2C19 (0.78) CYP2C19TSHRNR1H2NR1H3CNR2
SCHEMBL3747682 0.84 TDP1 (0.61) CYP2C19TSHRNR1H2NR1H3CNR2
SCHEMBL10763738 0.83 CYP2C19 (0.67) CYP2C19TSHRNR1H2NR1H3CNR2
SCHEMBL4407604 0.83 CYP2C19 (0.67) CYP2C19TSHRNR1H2NR1H3CNR2
SCHEMBL43183 0.82 TSHR (0.74) CYP2C19TSHRNR1H2NR1H3CNR2
SCHEMBL2957378 0.81 CYP2C19 (0.64) CYP2C19TSHRNR1H2NR1H3CNR2
SCHEMBL2011193 0.80 CYP2C19 (0.69) CYP2C19TSHRNR1H2NR1H3CNR2
SCHEMBL7154167 0.80 CYP2C19 (0.69) CYP2C19TSHRNR1H2NR1H3CNR2
SCHEMBL31374882 0.80 NR1H2 (0.57) CYP2C19TSHRNR1H2NR1H3CNR2
Hydrochloric Acid SCHEMBL2139953 0.80 TSHR (0.71) CYP2C19TSHRNR1H2NR1H3CNR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100292214-A1 Compounds with Antiparasitic Activity, Applications thereof to the Treatment of Infectious Diseases Caused by Apicomplexans COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) 2010-11-18 US disclosed
EP-2155676-A2 COMPOUNDS WITH ANTIPARASITIC ACTIVITY, APPLICATIONS THEREOF TO THE TREATMENT OF INFECTIOUS DISEASES CAUSED BY APICOMPLEXANS Commissariat à l'Energie Atomique (FR) 2010-02-24 EP disclosed
WO-2008146172-A2 COMPOUNDS WITH ANTIPARASITIC ACTIVITY, APPLICATIONS THEREOF TO THE TREATMENT OF INFECTIOUS DISEASES CAUSED BY APICOMPLEXANS COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) 2008-12-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100292214-A1 Compounds with Antiparasitic Activity, Applications thereof to the Treatment of Infectious Diseases Caused by Apicomplexans ABCB11, TPP1, ABCB1 CYP2C19 515/4885TSHR 4703/4885NR1H2 1354/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.